Dr. Koen Van Besien, MD
Claim this profileWeill Cornell Medical College
Studies Acute Myelogenous Leukemia
Studies Acute Lymphoblastic Leukemia
15 reported clinical trials
23 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
Second relapse
Subsequent relapse
HLA-A positive
2Acute Lymphoblastic Leukemia
CD19 positive
Philadelphia chromosome positive
HLA-A positive
Affiliated Hospitals
Clinical Trials Koen Van Besien, MD is currently running
Tabelecleucel
for Post-Transplant Cancer
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Recruiting2 awards Phase 312 criteria
JCAR017
for Chronic Leukemia or Lymphoma
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
Recruiting1 award Phase 1 & 2
More about Koen Van Besien, MD
Clinical Trial Related7 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Koen Van Besien, MD has experience with
- AgenT-797
- Orca-T
- Tabelecleucel
- Unlicensed Cryopreserved Cord Blood Units
- PBCAR0191
- Fludarabine
Breakdown of trials Koen Van Besien, MD has run
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
Hematologic Malignancies
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Koen Van Besien, MD specialize in?
Koen Van Besien, MD focuses on Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved Second relapse patients, or patients who are Subsequent relapse.
Is Koen Van Besien, MD currently recruiting for clinical trials?
Yes, Koen Van Besien, MD is currently recruiting for 6 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Koen Van Besien, MD has studied deeply?
Yes, Koen Van Besien, MD has studied treatments such as agenT-797, Orca-T, Tabelecleucel.
What is the best way to schedule an appointment with Koen Van Besien, MD?
Apply for one of the trials that Koen Van Besien, MD is conducting.
What is the office address of Koen Van Besien, MD?
The office of Koen Van Besien, MD is located at: Weill Cornell Medical College, New York, New York 10021 United States. This is the address for their practice at the Weill Cornell Medical College.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.